The association between the p53/topoisomerase I and p53/ topoisomerase IIalpha immunophenotypes and the progression of ovarian carcinomas.
The association between the p53/topoisomerase I and p53/ topoisomerase IIalpha immunophenotypes and the progression of ovarian carcinomas.
复制标题
p53/拓扑异构酶 I 和 p53/拓扑异构酶 IIα 免疫表型与卵巢癌进展之间的关联。
DOI：
10.1042/bj3610027
复制
发表时间：
2012
期刊：
影响因子：
--
通讯作者：
M. Jeleń
中科院分区：
文献类型：
--
作者：
J. Bar;P. Grelewski;L. Noga;J. Rabczyński;M. Gryboś;M. Jeleń
背景
体外研究表明，p53 蛋白表达可能调节肿瘤细胞中的拓扑异构酶 I (topo I) 和拓扑异构酶 IIalpha (topo IIalpha) 水平。迄今为止，p53蛋白与topo I和topo IIα表达之间的关联及其对卵巢癌进展的影响尚未被分析。
目标
该研究的目的是检查拓扑 I 和拓扑 IIα 表达与 p53 蛋白过度表达与卵巢肿瘤形态特征和进行性生长之间的关系。
材料和方法
通过对 136 例恶性卵巢肿瘤和 30 例良性卵巢肿瘤的肿瘤切片进行免疫组织化学染色来评估所研究的生物标志物的表达。
结果
恶性肿瘤和良性肿瘤之间拓扑结构 I、拓扑结构 IIα 和 p53 表达存在显着差异 (p < 0.01)。 topo IIalpha 和 p53 蛋白的表达与卵巢癌的晚期阶段相关 (p < 0.01)。 Topo I 阳性病例与低 (G1) 和高 (G3) 肿瘤分级之间的差异仅具有临界意义 (p = 0.07)。在卵巢癌中，topo I 和 topo IIalpha、topo I 和 p53 以及 topo Ilalpha 和 p53 蛋白表达之间呈正相关 (p = 0.001)。在良性卵巢肿瘤中未发现所研究的生物标志物之间存在相关性 (p > 0.05)。 p53/topo I 和 p53/topo IIalpha 免疫表型与卵巢癌晚期相关（分别为 p = 0.045 和 p = 0.009），p53/topo IIalpha 阳性卵巢癌在高肿瘤级别中比在低肿瘤级别中更常见，并且差异仅具有临界意义（p = 0.07）。
结论
目前的研究结果表明，一方面，topo I、topo IIα和p53蛋白之间的协同作用参与了卵巢肿瘤的进行性生长。另一方面，所研究的蛋白质的同时表达识别出具有侵袭性生物学特征的卵巢癌亚组，可以在治疗中考虑这些特征。
BACKGROUND
In in vitro studies it has been revealed that p53 protein expression might regulate topoisomerase I (topo I) and topoisomerase IIalpha (topo IIalpha) levels in tumor cells. So far, the association between the p53 protein and topo I and topo IIalpha expression and its impact on ovarian carcinoma progression has not been analyzed.
OBJECTIVES
The aim of the study was to examine the association between topo I and topo IIalpha expression and p53 protein overexpression with respect to the morphological features and progressive growth of ovarian tumors.
MATERIAL AND METHODS
The expression of the studied biomarkers was estimated by immunohistochemical staining in tumor sections from 136 malignant and 30 benign ovarian neoplasms.
RESULTS
Significant differences for topo I, topo IIalpha and p53 expression between malignant and benign tumors were observed (p < 0.01). The expression of topo IIalpha and p53 protein was associated with advanced stages of ovarian carcinomas (p < 0.01). Differences between topo I-positive cases and low (G1) and high (G3) tumor grade had only borderline significance (p = 0.07). In ovarian carcinomas, positive correlations between topo I and topo IIalpha, topo I and p53 and topo Ilalpha and p53 protein expression were revealed (p = 0.001). No relationship between the studied biomarkers was found in benign ovarian tumors (p > 0.05). p53/topo I and p53/topo IIalpha immunophenotypes were associated with advanced stages of ovarian carcinoma (p = 0.045 and p = 0.009, respectively), p53/topo IIalpha positive ovarian carcinomas were more frequently observed in high than in low tumor grades and the differences were only of borderline significance (p = 0.07).
CONCLUSIONS
Current findings suggest that on the one hand, cooperation between topo I, topo IIalpha and p53 protein participates in the progressive growth of ovarian tumors. On the other hand, simultaneous expression of the studied proteins identifies the subgroup of ovarian cancers with aggressive biological features which might be considered in therapy.
体内拓扑异构酶 I 募集的 p53 依赖性。
影响因子：
11.2
作者：
Mao,Y;Okada,S;Chang,LS;Muller,MT
通讯作者：
Muller,MT